FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2402118635> ?p ?o ?g. }

• W2402118635 abstract "CRISPR (clustered regularly interspaced short palindromic repeats) is an adaptive genome defense system in bacteria and archaea. CRISPR has been widely repurposed as an RNA-guided genome editing method. We have shown that the endonuclease domains of the Cas9 protein can be mutated to create a programmable RNA-guided DNA-binding protein. In human cells, we have shown we can control transcription of endogenous coding and non-coding genes over a wide range (up to 1000 fold) by using dCas9 chimeras to deliver protein domains that either repress (CRISPRi) or activate (CRISPRa) transcription. These experiments provide proof of principle that we can use dCas9 as an RNA-guided DNA binding platform to deliver in theory any protein to a specific genomic location, which may be useful for studying transcription, epigenetic regulation, DNA replication and DNA repair. We have developed a genome-scale CRISPRi/a functional genomics platform for loss- and gain-of-function screening in human cells. We have demonstrated that our CRISPRi/a screening platform can robustly identify pathways and proteins required for cancer cell growth and survival. Gain-of-function CRISPRa screens promise to reveal a layer of genetic information missing from previous efforts. We have shown in a cell growth screen that CRISPRa reveals latent tumor suppressors and transcription factors that regulate cancer cell state in chronic myeloid leukemia cells. In proof of principle, we have also used CRISPRi/a screens to determine the mechanism of cellular uptake, trafficking, retro-translocation, and toxicity for a chimeric bacterial toxin. These experiments establish CRISPRi and CRISPRa as powerful tools that provide rich and complementary information for mapping complex pathways. Recently, we have used our CRISPRi/a functional genomics platform to determine the genetics of cellular response to HSP70 inhibitors, which are a new class of anti-cancer drugs targeting a non-oncogene addiction. Together, our experiments demonstrate the utility of our CRISPRi/a functional genomics approach for studying principles of oncogene and non-oncogene addiction in cancer biology and cancer therapy. Citation Format: Luke A. Gilbert, Max A. Horlbeck, Jacqueline Villalta, Shao Hao, Jason E. Gestwicki, Jonathan S. Weissman. Retooling CRISPR to turn genes on and off. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr IA27." @default.
• W2402118635 created "2016-06-24" @default.
• W2402118635 creator A5006760859 @default.
• W2402118635 creator A5035219354 @default.
• W2402118635 creator A5044317285 @default.
• W2402118635 creator A5064492496 @default.
• W2402118635 creator A5067529915 @default.
• W2402118635 creator A5073914369 @default.
• W2402118635 date "2016-02-01" @default.
• W2402118635 modified "2023-09-27" @default.
• W2402118635 title "Abstract IA27: Retooling CRISPR to turn genes on and off" @default.
• W2402118635 doi "https://doi.org/10.1158/1538-7445.fbcr15-ia27" @default.
• W2402118635 hasPublicationYear "2016" @default.
• W2402118635 type Work @default.
• W2402118635 sameAs 2402118635 @default.
• W2402118635 citedByCount "0" @default.
• W2402118635 crossrefType "proceedings-article" @default.
• W2402118635 hasAuthorship W2402118635A5006760859 @default.
• W2402118635 hasAuthorship W2402118635A5035219354 @default.
• W2402118635 hasAuthorship W2402118635A5044317285 @default.
• W2402118635 hasAuthorship W2402118635A5064492496 @default.
• W2402118635 hasAuthorship W2402118635A5067529915 @default.
• W2402118635 hasAuthorship W2402118635A5073914369 @default.
• W2402118635 hasConcept C104317684 @default.
• W2402118635 hasConcept C132455925 @default.
• W2402118635 hasConcept C145290725 @default.
• W2402118635 hasConcept C41091548 @default.
• W2402118635 hasConcept C54355233 @default.
• W2402118635 hasConcept C67705224 @default.
• W2402118635 hasConcept C70721500 @default.
• W2402118635 hasConcept C86803240 @default.
• W2402118635 hasConcept C97702854 @default.
• W2402118635 hasConcept C98108389 @default.
• W2402118635 hasConceptScore W2402118635C104317684 @default.
• W2402118635 hasConceptScore W2402118635C132455925 @default.
• W2402118635 hasConceptScore W2402118635C145290725 @default.
• W2402118635 hasConceptScore W2402118635C41091548 @default.
• W2402118635 hasConceptScore W2402118635C54355233 @default.
• W2402118635 hasConceptScore W2402118635C67705224 @default.
• W2402118635 hasConceptScore W2402118635C70721500 @default.
• W2402118635 hasConceptScore W2402118635C86803240 @default.
• W2402118635 hasConceptScore W2402118635C97702854 @default.
• W2402118635 hasConceptScore W2402118635C98108389 @default.
• W2402118635 hasLocation W24021186351 @default.
• W2402118635 hasOpenAccess W2402118635 @default.
• W2402118635 hasPrimaryLocation W24021186351 @default.
• W2402118635 hasRelatedWork W10791717 @default.
• W2402118635 hasRelatedWork W11831921 @default.
• W2402118635 hasRelatedWork W14581506 @default.
• W2402118635 hasRelatedWork W17198291 @default.
• W2402118635 hasRelatedWork W18990239 @default.
• W2402118635 hasRelatedWork W25389013 @default.
• W2402118635 hasRelatedWork W25624748 @default.
• W2402118635 hasRelatedWork W4839031 @default.
• W2402118635 hasRelatedWork W5940357 @default.
• W2402118635 hasRelatedWork W800577 @default.
• W2402118635 isParatext "false" @default.
• W2402118635 isRetracted "false" @default.
• W2402118635 magId "2402118635" @default.
• W2402118635 workType "article" @default.